Get started
Author

Sivatharshini Ramalingam

Observed name: Ramalingam, Sivatharshini
ORCID: 0009-0009-2582-9548
Observed ORCID: 0009-0009-2582-9548
OpenAlex ID: A5061062473
Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology
2024 · Carlo Gabriele Tocchetti, Dimitrios Farmakis, et al. · European Journal of Heart Failure · 91
Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer
2021 · Nicolò Matteo Luca Battisti, Maria Sol Andres, et al. · Breast Cancer Research and Treatment · 82
PDF
Cardiovascular Considerations Before Cancer Therapy
2024 · Zahra Raisi-Estabragh, Alexandra C. Murphy, et al. · JACC CardioOncology · 76
The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment
2022 · Maria Sol Andres, Sivatharshini Ramalingam, et al. · Cardio-Oncology · 33
PDF
Risk Assessment Prior to Cardiotoxic Anticancer Therapies in 7 Steps
2025 · Jieli Tong, Isabelle Senechal, et al. · British Journal of Hospital Medicine · 12
PDF
Chronic Obstructive Pulmonary Disease and the Management of Cardiopulmonary Risk in the UK: A Systematic Literature Review and Modified Delphi Study
2025 · Dinesh Shrikrishna, John Steer, et al. · International Journal of COPD · 9
PDF
The United Kingdom’s First Cardio-Oncology Service
2024 · Maria Sol Andres, Theodore Murphy, et al. · JACC CardioOncology · 9
Complementary use of cardiac magnetic resonance and 18 F-FDG positron emission tomography imaging in suspected immune checkpoint inhibitor myocarditis
2024 · Jieli Tong, Nikolaos Vogiatzakis, et al. · Cardio-Oncology · 8
PDF
Evolving cardiac biomarkers for immune checkpoint inhibitor related myocarditis in cancer patients
2023 · Suprateeka Talukder, Aruni Ghose, et al. · IJC Heart & Vasculature · 8
Late cardiotoxicity related to HER2-targeted cancer therapy
2024 · Isabelle Senechal, Maria Sol Andres, et al. · Cardio-Oncology · 6
PDF
Risk Stratification, Screening and Treatment of BRAF/MEK Inhibitors-Associated Cardiotoxicity
2024 · Isabelle Senechal, Maria Sol Andres, et al. · Current Oncology Reports · 4
Immunotherapy and the heart: Understanding the cardiovascular risks of immune checkpoint inhibitors
2025 · Maria Sol Andres, Maria Clara Llamedo, et al. · La Presse Médicale · 3
Clinical Utility and Prognostic Value of Coronary Computed Tomography Angiography in Patients With Cancer
2023 · Muhummad Sohaib Nazir, Theodore Murphy, et al. · The American Journal of Cardiology · 3
PDF
Imaging Immune Checkpoint Inhibitor Myocarditis
2025 · Edward Doris, Charlotte Manisty, et al. · JACC CardioOncology · 2
Cancer therapy related cardiac dysfunction as a result of Panitumumab
2024 · Isabelle Senechal, Nikolaos Vogiatzakis, et al. · Cardio-Oncology · 2
PDF
Personalized cancer care can’t rely on molecular testing alone
2024 · James Larkin, Chloe Beland, et al. · Nature · 2
Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement
2026 · Susan Dent, Michelle B. Nadler, et al. · Cardio-Oncology · 1
PDF
Right Heart Assessment in Cancer Patients: Call to Action
2025 · Sivatharshini Ramalingam, Julia Toste, et al. · Echocardiography · 1
PDF
Comorbidity patterns and their associations with performance status and treatment receipt in breast and colorectal cancers in a multiethnic Asian setting: a latent class analysis
2026 · Yee-Yin Hoo, Huah Shin Ng, et al. · Supportive Care in Cancer
Machine learning—enhanced baseline risk prediction models for cancer therapy related cardiac dysfunction: a systematic review and critical appraisal of methodological quality
2026 · Maria Sol Andres, Vijay Maharahan, et al. · European Heart Journal - Digital Health
Correction: Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement
2026 · Susan Dent, Michelle B. Nadler, et al. · Cardio-Oncology
PDF
Correction: Prevention and management of cardiovascular disease in adults with cancer: an International Cardio‑Oncology Society (IC‑OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement
2026 · Susan Dent, Michelle B. Nadler, et al. · Supportive Care in Cancer
PDF
124 Bridging the gap: integrating cardio-oncology education into the undergraduate medical curriculum
2026 · Mari Baker, Matilda Howe, et al.
PDF
Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement
2026 · Susan Dent, Michelle B. Nadler, et al. · Supportive Care in Cancer
PDF
A risky business: recalibrating the future of cardiovascular risk prediction in cancer survivors
2026 · Lorcan Ruane, Sivatharshini Ramalingam, et al. · European Journal of Preventive Cardiology
Works count: 29
Citation count: 352
H-index: 8
I10-index: 5
Year
Topic
Type